PTX News Alert Pernix Therapeutics Holdings Inc. (PTX) 9.05 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pernix Therapeutics Holdings Inc. (PTX) 9.05 $PTX

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Pernix Therapeutics Inc. to Present at the Oppenheimer Healthcare Conference in New York, NY
Business Wire - Mon Dec 01, 7:00AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ TX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer and Sanjay Patel, Chief Financial Officer, are scheduled to present at the Oppenheimer Healthcare conference in NYC on December 11, 2014.
PTX: 9.05 (+0.28)

Pernix Therapeutics Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Nov 24, 7:37AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that Douglas Drysdale, Chairman, President and Chief Executive Officer and Sanjay Patel, Chief Financial Officer, are scheduled to present at the Annual Piper Jaffray Healthcare Conference in New York, NY on December 2, 2014.
PTX: 9.05 (+0.28)

Pernix Submits sNDA for TREXIMET(R) Use in Adolescent Patients
Business Wire - Mon Nov 17, 6:39AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ TX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TREXIMET (sumatriptan / naproxen sodium) to seek approval for use in adolescent patients, age 12 - 17, for the acute treatment of migraine with or without aura.
PTX: 9.05 (+0.28)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
PGNX: 6.99 (-0.03), ICUI: 83.38 (+1.63), CDZI: 11.78 (+0.05), INSY: 41.52 (+0.51), PCMI: 9.51 (-0.38), PTX: 9.05 (+0.28), CYAN: 7.00 (+0.50), ACHN: 13.06 (+1.22), AGIO: 109.67 (+2.45), LIOX: 5.82 (+0.05), PLNR: 7.04 (-0.15)

Midday gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:45AM CST

FSM: 4.31 (+0.10), HEAR: 2.98 (+0.01), JRJC: 5.81 (-0.11), CVO: 2.13 (-0.03), AAOI: 10.75 (-0.05), UNIS: 3.19 (+0.03), HIIQ: 7.51 (-0.16), CYAN: 7.00 (+0.50), PTX: 9.05 (+0.28), TRMR: 2.74 (-0.08), PRKR: 0.90 (+0.04), SUMR: 3.10 (+0.06), VSLR: 8.97 (+0.18), RVP: 4.84 (+0.19), ASCMA: 53.62 (+0.92), ICUI: 83.38 (+1.63), CALL: 7.83 (-0.07), DMD: 5.96 (-0.09), AST: 3.22 (+0.01), ASEI: 51.61 (+0.05)

Pernix Therapeutics Holdings' (PTX) CEO Douglas Drysdale on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:46PM CST

PTX: 9.05 (+0.28)

Pernix Therapeutics ups revenues 72% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:15PM CST

PTX: 9.05 (+0.28)

Pernix Therapeutics Holdings (PTX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:55AM CST

PTX: 9.05 (+0.28)

Pernix Therapeutics misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:09AM CST

PTX: 9.05 (+0.28)

Pernix Therapeutics Reports Third Quarter 2014 Financial Results and Reaffirms Guidance
Business Wire - Mon Nov 10, 7:01AM CST
--Company Reiterates Full Year 2014 and 2015 Guidance
PTX: 9.05 (+0.28)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.61 (+0.06), PTX: 9.05 (+0.28), AKRX: 36.47 (+0.43), RPRX: 8.88 (+0.24), NKTR: 15.02 (+0.23)

Pernix reports November 10
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 10:53AM CDT

PTX: 9.05 (+0.28)

Pernix Therapeutics to Report Q3 2014 Financial Results
Business Wire - Mon Oct 27, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ TX), a specialty pharmaceutical company, today announced that it will release its third quarter 2014 financial results on Monday, November 10, 2014 and has scheduled a conference call at 10:00 a.m. EST.
PTX: 9.05 (+0.28)

5 Stocks Under $10 Set to Soar
at The Street - Fri Oct 17, 8:41AM CDT
These under-$10 stocks look ready to trade higher from current levels.
GOMO: 5.00 (-0.05), ARWR: 6.35 (+0.07), PTX: 9.05 (+0.28), ADHD: 4.00 (+0.24), ZQK: 2.43 (-0.06), SALT: 2.06 (-0.06)

3 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 15, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HGG: 7.65 (-0.12), PTX: 9.05 (+0.28), IVAC: 8.13 (+0.10)

5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Sep 26, 1:16PM CDT
These under-$10 stocks look ready to trade higher from current levels.
PTX: 9.05 (+0.28), TGS: 3.51 (-0.02), RPRX: 8.88 (+0.24), NQ: 4.32 (-0.36), CVGI: 6.72 (-0.13)

Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.
Business Wire - Wed Aug 20, 7:01AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company" , a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix first announced its agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet(R) on May 14. Pernix's expanded team of approximately 100 specialty sales professionals will support the sales and marketing of Treximet(R). The Company will hold a conference call on Wednesday, August 20 at 9:00 a.m. EDT to discuss this acquisition.
PTX: 9.05 (+0.28), GSK: 42.85 (+0.11), POZN: 7.86 (+0.07)

POZEN Announces U.S. Rights For TREXIMET(R) Have Been Acquired by Pernix Therapeutics
Business Wire - Wed Aug 20, 7:00AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the acquisition of all of GlaxoSmithKline's (GSK) rights to Treximet(R) (sumatriptan / naproxen sodium) have been acquired by Pernix Therapeutics Holdings, Inc. (Pernix). The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix have amended the agreement to address rights of the parties and future development.
PTX: 9.05 (+0.28), GSK: 42.85 (+0.11), POZN: 7.86 (+0.07)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 41

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 72

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 117

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 111

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 83

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Fluor Corporation Investors Alert: Join the Class Action Now

Updated Category News Views 153

Fluor Corporation Class Action Overview The Portnoy Law Firm has issued an important announcement regarding Fluor Corporation's recent class action lawsuit. Investors who purchased securities of Fluor during a specified period are encouraged to participate. Details of the Class Action This class action is targeting investors who acquired Fluor Corporation shares from...

Continue Reading
Maravai LifeSciences Investors: Are You Affected by Recent Issues?

Updated Category News Views 141

Maravai LifeSciences Holdings, Inc. Overview Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has quickly become a pivotal player in the biopharmaceutical sector. Their innovative approach and dedication to improving scientific methods have attracted attention from investors and stakeholders alike. However, recent events have thrown some uncertainty into the landscape...

Continue Reading
Gesa Credit Union Acquires Willamette Valley Bank

Updated Category News Views 73

Community Banking Shake-Up in the Pacific Northwest Ah, mergers and acquisitions—they’re like spices in the economic salsa. Today's special? Gesa Credit Union, one of Washington’s powerhouses, deciding to acquire Willamette Valley Bank. Nothing gets the business blood pumping like a good ol' fashioned acquisition. The Financial Backdrop This deal isn't some casual...

Continue Reading
Market Uncertainty Eases as Economic Data Floods In

Updated Category News Views 181

Market Uncertainty Eases as Economic Data Floods In The US government shutdown has come to an end. However, as soon as the funding bill was signed, the markets shifted their focus toward the substantial economic data that has been delayed for over six weeks. This hiatus lasted for forty-three days without any federal reporting, resulting in a significant gap in available...

Continue Reading
AIM Congress 2026: Shaping Future Investment Pathways

Updated Category News Views 510

Exciting News About AIM Congress 2026 The Organizing Committee of AIM Congress, the foremost investment platform globally, has announced the launch of its 15th edition, centered around the compelling theme: Reshaping Global Prosperity: Unlocking New Investment Pathways Towards a Sustainable and Inclusive Future. This prestigious event is set to take place in April 2026 at...

Continue Reading